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REVIEW
Abstract: Etanercept (ETN) is the first anti-tumor necrosis factor (TNF) agent to be approved
for the treatment of rheumatoid arthritis (RA). Over the last 8 years, several clinical trials
have shown its efficacy and safety in established and early RA, as well as a monotherapy or
in combination with methotrexate. ETN not only reduces the signs and symptoms of RA, but
also retards the progression of radiographic damage and improves the quality of life and
function of patients. Its safety profile has been predictable since the first clinical trials with
no new major safety concerns. Beyond its efficacy in RA, ETN is also indicated for the
treatment of psoriatic arthritis. This current report reviews the evidence and the data in RA
and psoriatic arthritis (PsA).
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Introduction
In the last decade, the treatment of rheumatoid arthritis (RA) has undergone a major
revolution. The advent of targeted therapies, mainly against tumor necrosis factor-
alpha (TNF-α) and the development of new therapeutic strategies of their early
combination with traditional disease modifying anti-rheumatic drugs (DMARD), in
particular methotrexate (MTX) and the aim of achieving clinical remission, have
dramatically changed the management and hence the prognosis of RA. Etanercept
(ETN) was the first biologic response modifier to be approved by the US Food and
Drug Administration (FDA) for use in RA. The focus of this current review is the
efficacy and safety as well as the current positioning of ETN in the treatment of RA.
Molecular structure and mode of action
Etanercept is a dimeric human tumor necrosis factor receptor (TNFR) p75-Fc fusion
protein made of 2 extra-cellular domains of the human 75 kD (p75) TNFR linked by
the constant Fc portion of human immunoglobulin 1 (IgG1). Etanercept is produced
by recombinant DNA technology in Chinese hamster ovary (CHO) mammalian cell
expression system. It consists of 934 amino acids and has an approximate molecular
weight of 150 kD.
TNF is a naturally occurring cytokine produced primarily by activated
macrophages and T cells and exists predominantly as a trimer (Beayert and Fiers
1998; Krakauer et al 1999; Locksley et al 2001; McDermott 2001). Two distinct
receptors for TNF exist naturally as monomeric molecules on cell surfaces and in
soluble forms. One is a 55 kD protein (p55) and the other has a molecular weight of
75 kD (p75). The biological activity of TNF is dependent upon binding to either cell
surface TNFR. Monomers of the extracellular portion of the TNFRs naturally cleaved
from the cell surface are termed soluble TNF receptors (sTNFR). sTNFRs bind with
high affinity to circulating TNF and act as natural antagonists to TNF preventing the
TNF molecules from binding to cell-bound receptors.
The dimeric structure of ETN enhances its binding affinity and provides
substantially greater competitive inhibition of TNF than monomeric soluble receptors.
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Use of an IgG Fc region as a fusion element in this
construction imparts a longer serum half-life compared with
monomeric soluble receptors.
Etanercept inhibits in vitro the activity of human TNF
and is efficacious in many in vivo models of inflammation,
including arthritis. Etanercept competitively inhibits the
binding of both TNF-α and TNF-β (lymphotoxin-α [LT-
α]) to cell surface TNF receptors, rendering TNF
biologically inactive (Mohler et al 1993).
Etanercept also modulates indirectly different biological
responses that are induced or regulated by TNF, such as the
expression of adhesion molecules E-selectin and to a lesser
extent intercellular adhesion molecule 1 (ICAM-1), the
production of interleukin-6 (IL-6) and matrix
metalloproteinase 3 (MMP-3) (stromelysin), as well as IL-
1 (Verschueren et al 1999; Cartina et al 2002).
The immune function of patients with RA who are treated
with ETN has been extensively studied (Berg et al 2001;
Moreland et al 2002). T-cell responsiveness to microbial
antigens as well to collagen type II is not altered. No
significant differences are noted between patients treated
with ETN or placebo in the phenotypes of peripheral blood
leukocytes, T-cell proliferative responses, neutrophil
function, delayed type hypersensitivity reactions or serum
IgG levels.
Human pharmacokinetics
The pharmacokinetics of ETN were studied in
approximately 300 subjects with doses ranging from
0.125 mg/m
2 to 60 mg/m
2 administered by a single
intravenous (IV) infusion over 30 minutes or by single and
multiple subcutaneous (SC) injections. Following a single
administration of 25mg SC to 26 healthy volunteers, the
peak serum concentration is reached after a mean of 51 hours
with a maximum concentration (Cmax) of 1.46 mcg/ml (range
0.37–3.47) (Korth-Bradley et al 2000). The elimination half-
life is 68 hours. A twice weekly dosing regimen was devised
to maintain a steady-state concentration. Analyses of serum
samples from adult RA patients in long-term treatment trials
show stable steady-state concentrations of ETN. Recently,
a study comparing this traditional dosing regimen with a
once weekly injection of 50 mg showed comparable efficacy
and pharmacokinetics (Keystone et al 2005). However this
study was relatively short; further data using the 50 mg once
a week dosing regimen for a longer period of time and
assessing radiographic progression are needed.
There is no need for dose adjustment in the presence of
renal and/or hepatic impairment. No differences have been
observed in pharmacokinetics between men and women.
Clearance and volume estimates in patients aged 65 to 87
years are similar to those for patients less than 65 years of
age. Concomitant MTX administration does not alter the
pharmacokinetics of ETN.
Efficacy of etanercept in
rheumatoid arthritis
Numerous trials have demonstrated the efficacy and safety
of ETN in RA. Five major clinical trials are reviewed here.
The first randomized phase II trial demonstrating its efficacy
in patients with RA was in 1997 (Moreland et al 1997).
This was followed by evidence of its efficacy in patients
with RA who had suboptimal response to MTX in a 24-
week, double-blind randomized controlled trial (Weinblatt
et al 1999). In this study, 89 patients with persistently active
RA despite
 at least 6 months of MTX therapy on a stable
dose of 15–25 mg per week were assigned to receive either
ETN
 (25 mg) or placebo SC twice weekly while continuing
their stable dose of MTX. The primary measure of clinical
response
 was the American College of Rheumatology
criteria for a 20% improvement in measures of disease
activity (ACR20).
 At 24 weeks, 71 %
 of the patients
receiving ETN plus MTX versus 27 % of those receiving
placebo plus MTX met the
 ACR20 criteria (p<0.001); 39 %
of the patients receiving
 ETN plus MTX and 3 % of those
receiving placebo plus MTX reached an ACR50 response
(p<0.001). Patients receiving both treatments had
significantly better outcomes of all measures of disease
activity and the only adverse events associated with ETN
were mild injection-site reactions. No withdrawals occurred
due to adverse events
 associated with ETN.
Etanercept was studied as monotherapy for patients with
early RA. Bathon and colleagues (2000) studied 632 patients
with early rheumatoid arthritis
 with either twice-weekly
subcutaneous ETN (10 mg or 25 mg) or weekly oral MTX
(mean dose 19 mg per week) for 12 months. Although
patients who received the 25 mg dose of ETN had a more
rapid rate of improvement, with significantly more patients
achieving ACR 20%, 50%, and 70% improvement in
 disease
activity during the first six months (p<0.05) there was no
difference between the groups in these outcome measures
at 12 months. This was the first study to use rapidly escalated
dosing of MTX, which, since then set the standard for its
use in RA. However, rapid initial control of disease may
explain the difference in erosion scores between the two
groups. The mean increase in the erosion score during the
first 6 months
 was 0.30 in the 25mg ETN group versus 0.68Therapeutics and Clinical Risk Management 2007:3(1) 101
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in the MTX group (p=0.001), and the respective increases
during the first 12 months were 0.47 and 1.03 (p=0.002).
Among patients who received the 25 mg twice weekly (biw)
of ETN, 72
 % had no increase in the erosion score, versus
60% of patients in the MTX group (p=0.007).
 The ETN-
treated group of patients also had fewer adverse events
(p=0.02)
 and fewer infections (p=0.006) than the group that
was treated
 with MTX.
In none of the trials up to this point had ETN plus MTX
been compared with both ETN alone and MTX alone, in
MTX naïve patients. A three arm trial in established RA
patients, who averaged 6 years of disease duration, was
published by Klareskog and colleagues (2004) known as
the TEMPO trial (Trial of Etanercept and Methotrexate with
Radiographic Patient Outcomes). In this trial 682 patients
with active rheumatoid arthritis were randomly treated with
either ETN 25 mg (subcutaneously twice a week), oral MTX
alone (up to 20 mg every week), or the combination of MTX
and ETN. Efficacy of the combination therapy was
significantly greater at 24 weeks for the combination group
compared with ETN alone or MTX alone. The ACR20
responses were respectively for the 3 groups 85%, 76%,
and 75%); The ACR50 were at 69%, 48%, and 43%; finally
the ACR70 were 43%, 24%, and 19%. Moreover, 48% of
the patients in the combination group reached clinical
remission as defined by the EULAR Disease Activity Score
(DAS). The combination was also more efficacious than
MTX or ETN alone in retardation of joint damage (mean
total Sharp score –0·54 [95% confidence interval (CI) –1·00
to –0·07] vs 2·80 [1·08 to 4·51], p<0·0001, and 0·52 [–0·10
to 1·15], p=0·0006; respectively). The number of patients
reporting infections or adverse events was similar in all
groups. The authors concluded that the combination of ETN
and MTX was significantly better in reducing signs and
symptoms of RA, improving functional disability, and
retarding radiographic progression compared with MTX or
ETN alone. Therefore, unless contraindicated, it is
recommended to always combine ETN and MTX.
In daily clinical practice a great proportion of patients
still have active disease despite adequate doses of MTX
and hence require the addition of anti-TNF agents. The
question arises whether MTX needs to be continued or can
be safely stopped if treatment with ETN is initiated. This
issue was addressed in the ADORE trial (Add Enbrel or
Replace MTX) (Taggart et al 2005) which compared the
efficacy and safety of ETN plus MTX with ETN alone in
RA patients with an inadequate response to MTX therapy.
Patients with active RA (DAS28 ≥3.2 or ≥5 swollen and
painful joints and an ESR ≥10 mm/hr) despite treatment with
MTX ≥12.5 mg/wk for ≥3 months were randomly allocated
to twice weekly therapy of ETN (25 mg biw) and MTX
therapy or ETN 25 mg biw alone. The monotherapy group
of patients initially received ETN concurrently with MTX;
however, the MTX was discontinued over a period of 4
weeks. A Health Assessment Questionnaire (HAQ) was
administered at baseline and week 16 and EQ-5D and EQ-
5D general health visual analog scale (EQ-5D GH VAS) at
baseline, 4, 8, 12 and 16 weeks. Three hundred and fifteen
patients were randomized to ETA (n=160) or ETA–MTX
(n=155). At wk 16, both treatment groups demonstrated
important improvements in all three quality of life
assessments with no significant differences noted between
the two groups. The proportion of patients in the ETA–MTX
and ETA groups achieving improvements of HAQ ≥0.22
(73.8% vs 71.1%, respectively) and HAQ ≥0.5 (57.5% vs
59.2%) as well as a normal HAQ of ≤0.5 (32.6% vs 35.6%)
were similar. The same percentage of patients in the ETA–
MTX and ETA groups attained a Global Health score at or
above the population norms of ≥82 (31.4% vs 32.3%). Thus,
for patients with side effects or intolerance to MTX
switching treatment to ETN alone provides excellent
therapeutic improvements in physical function and quality
of life in the short term.
In a post hoc analysis, data from 4 trials were extracted
and a combined analysis of safety and efficacy of ETN in
patients who were ≥65 years to those <65 years was
completed (Flieschman et al 2003). All patients received
ETN subcutaneously twice weekly. Of 1128 patients
enrolled in ETN trials, 197 (17%) were ≥65 years of age.
Clinical response, assessed by the ACR 20%, 50% and 70%
was rapid and sustained and did not differ between age
groups. At one year, 69% of patients <65 years and 66% of
patients ≥65 years met the ACR20. Forty percent met the
ACR50 and 17% the ACR70. Although injection site
reactions, headache, and rhinitis occurred somewhat more
frequently in younger patients, the overall rates and types
of other adverse events were comparable in both groups
and ETN was well tolerated in the older age group.
Etanercept has most recently been shown to be effective
when given as in a once weekly dosing regimen of 50 mg
subcutaneously (Keystone et al 2005). In this study
evaluating pharmacokinetics, safety and efficacy of this new
dosing strategy in comparison with 25 mg SC biw 420 RA
patients were randomized to receive, in a blinded manner,
the study drug for up to 16 weeks: 214 patients received
50 mg ETN once weekly, 153 received 25 mg ETN biw, andTherapeutics and Clinical Risk Management 2007:3(1) 102
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53 received placebo for 8 weeks followed by 25 mg ETN
biw for 8 weeks. Efficacy and safety were assessed at weeks
8 and 16. The primary efficacy end point was achievement
of the ACR20 criteria at week 8. It was achieved by 50% of
the patients receiving 50 mg ETN once weekly, by 49% of
the patients receiving 25 mg ETN biw, and by 19% of the
patients in the placebo group (p≤0.0001 for each ETN group
vs placebo). Similarly, achievement of the ACR50 response
was attained by 18% of patients in each of the 2 ETN groups,
compared with 6% of patients in the placebo group (p<0.03
for each comparison). Pharmacokinetics of the 2 ETN
regimens were similar at steady state. No clinically
significant differences in efficacy or safety were observed
between the 2 ETN groups.
The number needed to treat (NNT) is a helpful composite
score for clinicians to help translate the results from clinical
trials and systematic reviews. A low number needed to treat
indicates that few patients would need to receive an agent
to achieve a designated outcome. Recently Osiri and
colleagues (2003) looked at the NNT from data in
rheumatology clinical trials with ETN based on the ACR20
improvement. They noted that for RA, ETN treatment for
six months had the smallest NNT (1.6; 95% CI 1.4 to 2.0).
Etanercept and patients driven
outcomes
The impact of ETN on health-related quality of life
(HRQOL) and functional status over time was analyzed in
533 RA patients who had been previously randomized in
trials of ETN (Yelin et al 2001). Initial improvement in
patient-centered outcomes including HAQ, physical
component and mental component summary scores of the
SF-36 were shown to be sustained over time in patients with
either long term or early stage disease. The impact of ETN
on healthcare use and employment was also evaluated in
260 patients with early RA from the Early Rheumatoid
Arthritis (ERA) trial (Lubeck et al 2001). Even though the
control group of patients who received ETN only at the
termination of the ERA study received it for a mean of 239
days, patients originally randomized to ETN for a mean of
882 days reported fewer patient visits, outpatient surgeries,
and hospital admissions for RA than controls. RA patients
who were employed at disease onset and originally
randomized to ETN had more hours of employment
compared with controls. These data suggest the possibility
of reducing healthcare utilization and increased employment
with the use of ETN for a relatively short period of time.
Efficacy of etanercept in psoriatic
arthritis
Etanercept has also been shown to be effective in psoriatic
arthritis (PsA) (Mease et al 2000). In this12 week
randomized, double blind controlled trial, 60 patients with
PsA and psoriasis were studied for efficacy and safety of
ETN (25 mg biw SC) or placebo. The PsA outcome measures
included the proportion of patients who met the Psoriatic
Arthritis Response Criteria (PsARC) and those who met the
ACR20 response criteria. Psoriasis endpoints included
improvement in the Psoriasis Area and Severity Index
(PASI) and improvement in prospectively identified
individual target lesions. Eighty seven percent of ETN-
treated patients met the PsARC compared with 23% of
placebo-controlled patients. The ACR20 was achieved by
73% of ETN-treated patients compared with 13% of
placebo-treated patients. Of the 19 patients in each treatment
group who could be assessed for psoriasis (≥3% body
surface area), five (26%) of ETN-treated patients achieved
a 75% improvement in the PASI, compared with none of
the placebo-treated patients (p=0·015). The median PASI
improvement was 46% in ETN-treated patients versus 9%
in placebo treated patients; similarly, median target lesion
improvements were 50% and 0, respectively.
Safety of ETN in the rheumatoid
arthritis trials and extension
studies
With the accumulated experience with the anti-TNF agents,
certain areas of safety concerns have emerged, namely:
serious infections, opportunistic infections including
reactivation of tuberculosis (TB), malignancy, and more
particularly lymphomas, autoimmune syndromes,
demyelinating conditions, and congestive heart failure.
Through December 2002, 3839 patients (8336 patient-
years exposure) were treated in clinical trials whereas
231 000 patients (423 000 patient-years exposure; all
indications) were treated.
Risk of infections with etanercept
Given that TNF-α plays an important role in host defence
against infection, inhibition of TNF-α is expected to
increases the risk of infection in patients treated with TNF-
α antagonists (Cunnae et al 2003). However, in all of the
ETN placebo-controlled double blind trials, no increase in
the frequency or the nature of infections were noted,Therapeutics and Clinical Risk Management 2007:3(1) 103
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including serious infections, between ETN- and placebo-
treated patients. Moreover, in the early RA trial, serious
infections were statistically higher in the MTX group
compared with the ETN-treated patients. Because of the
potential risk, it is recommended not to administer ETN to
patients with recurrent infectious episodes and to stop this
agent in the presence of infections requiring antibiotics. ETN
may be restarted once the infection has resolved, although
the decision to reinstate ETN therapy should be made on a
case by case basis.
Several studies have evaluated the frequency of
infections after ETN administration compared with the
frequency prior to initiation. In one study, the rate of
infection in 90 patients was compared with the rate of
infection one year prior to therapy. The results showed a
significant (~2 fold) increase in the incidence of recorded
infections following the initiation of therapy for year 0, for
year 1, and for year 2 respectively (Belostocki et al 2001).
Most infections were respiratory and the majority was not
serious. Similar findings were observed in another study of
168 patients followed over one year (Philips et al 2002). In
that study, nonserious infections were seen in 51% of
patients during ETN therapy compared with 19% in the
pretreatment period although the rate of serious infections
was comparable (1.8% vs 2.9%) before and after therapy.
TNF has been shown to be critical to the maintenance
of post-infectious granuloma generated in response to
microbial agents such as Mycobacterium Tuberculosis
(MTb), histoplasmosis, and other opportunistic infections.
From the post-marketing surveillance data available as of
December 2001 for 114 000 ETN-treated patients (150 000
patient-years) world-wide, 20 cases of TB have been
reported. The pattern of TB was consistent with significant
immunosuppression with 3 of the patients exhibiting a
miliary pattern. The median time of onset of reactivation
was 6 months. Since the expected incidence of TB in the
USA is 6–8/100 000 patient-years, it is unclear whether TB
is increased in ETN-treated patients over the general RA
population. Nevertheless, screening for latent TB with a
chest x-ray and Purified Protein Derivative Standard (PPD)
skin test is recommended. A positive PPD (≥5 mm) is an
indication for initiating therapy for latent TB using isoniazid
(INH) (for 9 months) or rifampin (for 4 months). Other
opportunistic infections have also been reported including
atypical mycobacterium (n=8), pneumocystis carini (n=5),
with a few cases of Candidiasis (n=3), crypotococcosis
(n=3), aspergillosis (n=2), and isolated cases of
histoplasmosis (n=1), listeria monocytogenes (n=1).
Whether these numbers reflect an increase relative to
conventional DMARDS is uncertain.
Autoimmunity and lupus-like reactions
In randomised control trials 11% of patients developed new
ANAs compared with 5% with placebo. With ETN 15%
developed anti-dsDNA antibodies compared with 4% of
placebo-treated patients. A recent study demonstrated that
prior to ETN 18% (10/56) patients had positive
anticardiolipin (ACA) and that after 6 months of treatment,
25% of patients tested positive. Increases were seen for both
IgG and IgM ACA. Increasing age, a higher number of prior
disease-modifying antirheumatic drugs and higher DAS28
were predictors of developing ACA (Jonsdotter et al 2004).
Anti-thyroid and antineutrophil cytoplasmic antibodies were
rarely found in the absence of a clinical picture indicative
of thryroiditis or vasculitis respectively (De Rycke et al
2005).
Shakoor and colleagues (2002) described four cases of
systemic lupus erythematosus (SLE)-like syndrome in
patients treated with ETN. Symptoms appeared 6 weeks–3
months after initiation of ETN. Clinical presentation with
the four cases included fever, malaise and arthritis; discoid
lupus rash; hypertension, arthritis and erythematosus facial
rash; and pleuritis and malar rash. Within 2–6 weeks,
symptoms resolved with drug withdrawal. Mohan and
colleagues (2002) used the FDA adverse event-reporting
system to identify 16 cases of new-onset SLE after ETN
use from November 1998 to February 2002, excluding
Shakoor and colleagues’ cases.
Malignancy and lymphoma
During the 2003 FDA review of safety with the TNF
antagonists, 70 cases of lymphoma were reported on 230 000
patients exposed to ETN. This would indicate the incidence
of lymphoma is about 2 to 3 cases per 10 000 patient-years
and the estimated rate in the normal population of 3 per
10 000 patient years (Wasko 2004). In the Swedish and other
European registries the risk of lymphoma has also been
shown to be increased in patients with RA (Askling et al
2005). Recently Wolfe and Michaud (2004a) examined the
rate of standardized incidence ratio (SIR) and predictors
for lymphoma in patients with RA and in RA patient subsets
by treatment group in 18 572 patients prospectively enrolled
in the National Data Bank for Rheumatic Diseases (NDB)
registry. Patients were surveyed biannually, and potential
lymphoma cases received detailed follow up. Results were
compared with the SEER (Survey, Epidemiology, and EndTherapeutics and Clinical Risk Management 2007:3(1) 104
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Results) cancer database to derive the expected number of
cases of lymphoma controlling for age and gender. The
overall SIR for lymphoma was 1.9 (95% CI 1.3–2.7). The
SIR for biologic use was 2.9 (95% CI 1.7–4.9) and for ETN,
with or without infliximab (INF), the SIR was 3.8 (95% CI
1.9–7.5) compared with 2.6 (95% CI 1.4–4.5) for INF (with
or without ETN). The SIR for MTX was 1.7 (95% CI 0.9–
3.2), and was 1.0 (95% CI 0.4–2.5) for those not receiving
MTX or biologics. Lymphoma was associated with higher
age, male gender, and education. They concluded that
lymphomas were increased in RA with the SIR being greatest
for patients receiving anti-TNF therapies and that there were
no statistical differences between ETA and INF therapies.
The increased lymphoma rates observed with anti-TNF
therapy was thought to reflect channeling bias, whereby
patients with the highest risk of lymphoma (those with more
severe disease) preferentially receive anti-TNF therapy and
no causative relationship could be established on registry
data. Very recently, a review of lymphoproliferative
malignancies and solid tumors from 3 pharmacy databases
did not show any increase in the patients treated with anti-
TNF therapies when compared with patients treated with
MTX (Setogushi et al 2006)
Demyelinating syndromes
The number of cases of demyelination with ETN during
the clinical trials is still unclear. Mohan and colleagues
(2001) noted 17 cases of demyelination after ETN therapy.
All neurological events were temporally related to the use
of ETN with partial or complete resolution. The most
common presenting clinical symptoms among the 20
patients were paresthesias (13 of 20) followed by visual
disturbances secondary to optic neuritis (8 of 20). Other
signs and symptoms included confusion (25%), gait
disturbance, apraxia, facial palsy, and Guillain–Barré
syndrome. Four patients had multiple sclerosis.
Post-marketing observations did not show any increase
beyond the expected numbers.
Congestive heart failure and etanercept
Results from two prospective randomized, double-blind
trials comparing the effects of ETN and placebo in NYHA
functional class II-IV CHF patients underwent a combined
analysis (Mann et al 2004). The analysis showed no
beneficial effect on death or congestive heart failure (CHF)
hospitalization, with a relative risk of 1.11 (95% CI 0.91 to
1.33, p=0.33) for ETN compared with placebo. For overall
mortality, the estimated ETN-to-placebo relative risk was
1.13 (95% CI 0.86 to 1.50, p=0.39). Safety analysis of the
trials showed a trend (p=0.067) toward more overall
infections in the ETN-treated patients versus placebo in one
of the trials, but not in the second one.
In a recent review from the NDB registry, Wolfe and
Michaud (2004b) showed that there is a increased incidence
of CHF among RA patients and that anti-TNF agents may
improve this condition.
Conclusion
In summary, clinical trials show ETN is both safe and
effective to use in RA and PsA. In RA, ETN has been shown
not only to reduce disease activity but also to limit
progression of joint damage in early and late disease. ETN
can be used as a monotherapy or in combination with MTX,
although the latter approach appears most effective in terms
of reducing joint damage. Safety data in clinical trials have
shown no significant differences compared with placebo.
Thus the risk/benefit profile is manageable and ETN is a
valuable treatment option for patients with RA and PsA.
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